EN DE
Watch Senti Biosciences Holdings for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Senti Biosciences Holdings (SNTI) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Senti Biosciences Holdings stock $1.49, price $2.79, that is 46.6% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US81726A1007

SB Senti Biosciences Holdings logo Thin data Nov 20, 2026

Senti Biosciences Holdings

SNTI · US

Far too expensive (fair value 47% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Negative equity (buybacks among others) 
Fair value $1.49 · Strongly overvalued 
Quality 29/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −43.8 %/yr in USD) 
Negative free cash flow 
Trails peers (0/3) 
Narrow moat 18/100 · thin data
Thin data 
Estimate
Watch Senti Biosciences Holdings for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$3,379.20 $2.79 Fair Value $1.49 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.

How to read this chart

60‑month range $2.79 – $3,379.20 · fair‑value band $1.12 – $1.86 · the $2.79 price screens above the $1.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.

Follow Senti Biosciences in your weekly email

Every Wednesday you see whether Senti Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.

Show moreShow less

The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.

It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia.

In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.

Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines.

The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026.

The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Stock analysis

Senti Biosciences Holdings (SNTI) currently trades at $2.79, while our estimate is $1.49, 47% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.12 (bear) to $1.86 (bull), the price of $2.79 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Senti Biosciences Holdings reported revenue of $22.0K in FY2025 versus $2.3M in FY2021, a compound −68.7%/yr. Reported net income was −$61.4M in FY2025.

Key figures

Market cap $8.0M · EPS (TTM) $-46.20 · Return on equity −466% · Return on assets (EBIT) −69.1% (5-year average) · Operating margin −62,343% · Free cash flow −$43.6M · Net debt $12.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 96% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −47%, SNTI screens richer than that median.

Fair Value

Bear $1.12 Fair Value $1.49 Bull $1.86
Price $2.79 · Downside -46.6%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 19, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−82.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.8%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,267.5% (2020) → −289,668.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SNTI screens overvalued: fair value 47% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Senti Biosciences Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 0/3 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −46.6% · Bottom 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −119.9% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $923.34 $1,275.02 +38% vs SNTI
Vertex Pharmaceuticals Incorporated VRTX $520.66 $587.62 +13% vs SNTI
Samsung Biologics Co 207940 ₩1,375,000 ₩1,512,500 +10% vs SNTI
argenx SE ARGX $942.04 $908.40 −4% vs SNTI
CSL Limited CSL A$197.29 A$188.80 −4% vs SNTI
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs SNTI
Moderna, Inc MRNA $199.33 $122.98 −38% vs SNTI
Revolution Medicines, Inc RVMD $159.43 $83.12 −48% vs SNTI
Celltrion, Inc 068270 ₩215,000 ₩74,574 −65% vs SNTI
Royalty Pharma plc RPRX $67.72 $19.01 −72% vs SNTI

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Senti Biosciences Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Senti Biosciences Holdings Fair Value". https://www.fairvalue-calculator.com/stock/SNTI

Frequently asked questions

Is Senti Biosciences Holdings (SNTI) overvalued or undervalued?
As of Nov 20, 2026, our estimate of fair value is $1.49 versus a price of $2.79, about 47% lower (overvalued).
What is the fair value of SNTI?
Our estimate for Senti Biosciences Holdings is $1.49 (as of Nov 20, 2026), built from audited fundamentals. The current price: $2.79.
What is the quality score of SNTI?
Senti Biosciences Holdings has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Senti Biosciences Holdings (SNTI)?
We do not set a price target; the yardstick is our estimate of $1.49 (as of Nov 20, 2026). Cautious scenario $1.12, optimistic scenario $1.86. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Senti Biosciences Holdings stock forecast for 2026?
Our estimate puts fair value at $1.49, about 47% lower versus a price of $2.79 (overvalued). Cautious scenario $1.12, optimistic scenario $1.86. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Senti Biosciences Holdings (SNTI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Senti Biosciences Holdings it is $1.49 per share (as of Nov 20, 2026), against a price of $2.79.
Is Senti Biosciences Holdings stock overvalued or undervalued in 2026?
As of Nov 20, 2026, SNTI trades above its calculated fair value: price $2.79, fair value $1.49, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SNTI?
No. The price is what the market pays today ($2.79); the fair value is what the company's own numbers justify ($1.49). For Senti Biosciences Holdings the two are $1.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Senti Biosciences Holdings worth?
The market values Senti Biosciences Holdings at about $8.0M (market capitalisation, as of Nov 20, 2026). Per share that is $2.79; our models calculate a fair value of $1.49 per share.
What do the bullish and bearish scenarios say about SNTI?
Our models span a range for Senti Biosciences Holdings: cautious scenario $1.12, base $1.49, optimistic $1.86 per share (as of Nov 20, 2026, price $2.79). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Senti Biosciences Holdings (SNTI)?
Balance-sheet figures for Senti Biosciences Holdings (as of Nov 20, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is SNTI from its 52-week high?
Senti Biosciences Holdings trades at $2.79, about 96% below its 52-week high of $78.87 and at the low of $2.79 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of $1.49 is for.
Which stocks are comparable to Senti Biosciences Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Senti Biosciences Holdings stock attractive at the current price?
The data as of Nov 20, 2026: price $2.79, calculated fair value $1.49 (−47%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Senti Biosciences Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Senti Biosciences Holdings (SNTI)?
The closing price on Nov 19, 2026 was $2.79. Our estimate is $1.49, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Senti Biosciences Holdings right now?
The price sits above even our optimistic bull case ($1.86). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Senti Biosciences Holdings

How large is the market capitalisation of Senti Biosciences Holdings (SNTI)?
The market capitalisation of Senti Biosciences Holdings is $8.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Senti Biosciences Holdings (SNTI)?
Earnings per share at Senti Biosciences Holdings are $-46.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Senti Biosciences Holdings (SNTI)?
The return on equity (ROE) of Senti Biosciences Holdings is −466% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Senti Biosciences Holdings (SNTI)?
On an EBIT basis the return on assets of Senti Biosciences Holdings is −69.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Senti Biosciences Holdings (SNTI)?
The operating margin of Senti Biosciences Holdings is −62,343% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Senti Biosciences Holdings (SNTI) generate?
The free cash flow of Senti Biosciences Holdings is −$43.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Senti Biosciences Holdings (SNTI) carry?
The net debt of Senti Biosciences Holdings is $12.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Senti Biosciences Holdings in the live analysis

One click puts Senti Biosciences Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.